Japan Cancer Biomarker Market Growth, Size, Share, Industry Report and Forecast 2019-2025
Japan cancer biomarkers market is growing at a CAGR of around 11.9% during the forecast period. Japan market for biomarkers is expected to witness positive growth during forecast period. The mortality rate in Japan due to cancer is increasing day by day. The reason for mortalities due to cancer tobacco smoking. The increasing prevalence of cancer holds a promising market for biomarkers in Japan for the treatment of cancers. In 2017, there were around 1.1 million cases of cancer were registered in which 149,500 cases were of colon cancer followed by 132,800 cases of stomach cancer and 128,700 cases of lung cancer.
To Request a Sample of our Report on Japan Cancer Biomarker Market: https://www.omrglobal.com/request-sample/japan-cancer-biomarker-market
Further, the mortality due to cancer in Japan is estimated to around
0.37 million in 2017, which is also affecting the Japan cancer biomarker market
growth. According to the Tsugane’s contribution to cancer research, the
population attributable fraction (PAF) of tobacco smoking to cancer was 24%,
infection was 22%, alcohol drinking was 6%, and over-intake of salt was 1.4%.
The causes of the other 50% of cancer death were not sufficiently clarified.
Also studied the PAF for cancer incidence and found that it is almost the same
as that for cancer death.
In June 2017, Immunovia was granted a patent for biomarker signature for pancreatic cancer diagnosis. This was done for the success of IMMray PanCan-d test in Japan which is a commercial market for Immunovia. Safeguard R&D investment in such novel diagnostic tests Effective patent protection is vital in order. Additionally, in August 2017, Biomarker Strategies received two patent approvals, one for Snap Path and other for PathMAP technologies. Japan is in need to develop more targeted disease detection and treatments for a rapidly growing patient population, augmenting the market for Japan cancer biomarkers.
A
full Report of Japan Cancer Biomarker Market is Available at: https://www.omrglobal.com/industry-reports/japan-cancer-biomarker-market
Japan Cyber Security Market Segmentation
·
Network
Security
·
Application
Security
·
Mobile
Security
·
Wireless
Security
·
Cloud
Security
·
Others
By Solutions
·
Risk
and Compliance Management
·
Identity
and Access Management
·
Data
Loss Protection
·
Firewall
·
Unified
Threat Management
·
Encryption
·
Antimalware
and Antivirus
·
DDOS
mitigation
·
Others
(Security and Vulnerability Management, and Disaster Recovery)
By Vertical
·
Government
·
Aerospace
& Defence
·
BFSI
·
Telecommunication
·
Healthcare
·
Retail
·
Others
(Manufacturing, and Transportation)
Company
Profiles
·
Abbott
laboratories Inc.
·
Astellas
Pharma Inc.
·
Becton,
Dickson and Co.
·
Bio-Rad
Laboratories, Inc.
·
Danaher
Corp.
·
F.
Hoffmann-La Roche Ltd.
·
Merck
and Co., Inc.
·
Novartis
AG
·
Pfizer
Inc.
·
QIAGEN
GmbH
·
Thermo
Fisher Scientific Inc.
Reasons to Buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More Customized Data, Request for
Report Customization @ https://www.omrglobal.com/report-customization/japan-cancer-biomarker-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
For
More Information, Visit Orion Market Research
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment